ID Biotech 2026: HBV Cure, HIV Shift, 5 Catalysts

Infectious disease is the most boring sector in biotech until it is not. HIV generates $30 billion a year in global revenue. Hepatitis B affects 250 million people worldwide with no functional cure. Hepatitis C is commoditized. The next 12 months will reshape who wins and who loses across all three, and the catalysts are already on the FDA calendar. Here are the five that matter, ranked by risk-reward.

For the broader Q3 FDA calendar, we track every PDUFA date separately. This is the infectious disease sector deep dive.

1. Gilead BIC/LEN (PDUFA August 27): Gilead competing with Gilead

Gilead Sciences (GILD) closed at $132.73 with a $164.8 billion market cap. The FDA granted Priority Review for bictegravir/lenacapavir (BIC/LEN), a once-daily single-tablet HIV regimen, with a PDUFA date of August 27, 2026. The Phase 3 ARTISTRY-1 and ARTISTRY-2 trials showed BIC/LEN was noninferior to Biktarvy at maintaining virologic suppression at Week 48.

Here is the problem: Biktarvy generated $14.3 billion in 2025 revenue, up 7% year over year. It is Gilead’s crown jewel. BIC/LEN is not a new therapy for a new patient population. It is a switch regimen for patients already suppressed on Biktarvy or another antiretroviral. Noninferiority is not superiority. A daily single-tablet regimen that works as well as your own daily single-tablet regimen does not drive large-scale prescription switches. The net new revenue from BIC/LEN will be a fraction of its gross sales, because most patients switching to BIC/LEN are switching off Biktarvy. Gilead is competing with itself.

At GILD’s $164.8B market cap, this approval is immaterial to the stock price. The real HIV catalyst is the weekly ISL/LEN pill with Merck (PDUFA expected early 2027), which we analyzed the Gilead-Merck ISL/LEN weekly HIV pill separately. That is the shift from daily to weekly dosing. BIC/LEN is maintenance of the status quo. We also covered lenacapavir’s PrEP potential in our prior analysis.

2. GSK/Ionis bepirovirsen (PDUFA October 26): The first hepatitis B functional cure

GSK (GSK) closed at $53.22 with a $106.6 billion market cap. Ionis Pharmaceuticals (IONS) closed at $54.04 with an $8.93 billion market cap. Bepirovirsen is an antisense oligonucleotide targeting hepatitis B virus RNA, and the FDA granted Breakthrough Therapy Designation with a PDUFA date of October 26, 2026.

The B-Well 1 and B-Well 2 Phase 3 trials, published in NEJM, showed a 19% functional cure rate in the overall population (233 of 1,220 patients vs 0 of 614 on placebo, p<0.001 in both trials). In patients with baseline HBsAg at or below 1000 IU/mL, the functional cure rate was 26% (200 of 768 vs 0 of 393, p<0.001). Functional cure means HBV DNA and HBsAg are undetectable for at least 24 weeks after stopping all treatment. The current standard of care requires lifelong therapy with a functional cure rate under 1%.

This is the most clinically significant ID catalyst of 2026. Chronic hepatitis B affects 250 million people worldwide and accounts for roughly 56% of liver cancer cases. GSK estimates peak sales above £2 billion. For Ionis, bepirovirsen validates the antisense platform in infectious disease and earns 10 to 12% tiered royalties. For GSK, it adds a new franchise outside HIV and oncology.

The risk is the safety profile. Grade 3 or higher adverse events occurred in 16% of bepirovirsen recipients versus 3% on placebo, with ALT elevations being the most common (6%). The FDA will scrutinize the liver enzyme signals. But a 19% functional cure rate against a 0% placebo baseline is a data package that demands approval.

The subgroup enrichment strategy matters here. Patients with baseline HBsAg at or below 1000 IU/mL represent roughly 45% of diagnosed CHB cases globally, and they achieved a 26% cure rate. Patients with HBsAg between 1000 and 3000 IU/mL had cure rates of only 5 to 10%. This is a drug that works best in the lower-viral-load population. The label will likely reflect this stratification, which is clinically rational: the immune system needs a lower starting antigen burden to regain control after bepirovirsen suppresses viral replication. The commercial question is whether physicians can identify the right patients.

IONS at $8.93B already reflects a pipeline premium, but a bepirovirsen approval narrows the market cap gap with Alnylam ($37B) in the RNA therapeutics space. Ionis earns 10 to 12% tiered royalties on net sales. GSK estimates peak sales above £2 billion. At a 10% royalty on £2B in peak sales, Ionis earns roughly £200M annually, or about $260M. Against an $8.93B market cap, that is a 2.9% royalty yield. The thesis is not the royalty stream alone. It is the platform validation that attracts more partnerships and de-risks the rest of the antisense pipeline.

3. Gilead/Merck ISL/LEN weekly (PDUFA expected early 2027): The real HIV dosing shift

The ISL/LEN combination (islatravir/lenacapavir) is an oral once-weekly HIV pill. The Phase 3 ISLEND-1 trial showed zero virologic failures, and the NDA is expected to file in late 2026 with a PDUFA date in early 2027. This is the catalyst that changes HIV treatment. A weekly pill replaces a daily pill. Adherence improves. The $30 billion HIV market shifts from daily single-tablet regimens to weekly dosing.

For Gilead, ISL/LEN is both defensive and offensive. It protects the lenacapavir franchise (Sunlenca, approved for heavily treatment-experienced patients) by expanding into the mainstream treatment market. For Merck, it is the first meaningful HIV revenue stream. Merck partnered with Gilead because islatravir (Merck’s NRTI) pairs with lenacapavir (Gilead’s capsid inhibitor) in a mechanism neither company could deliver alone.

The comp comparison: GSK/ViiV’s Cabenuva is a monthly injectable that has been winning on convenience, with Dovato sales growing 22% to £2.7B in 2025. A weekly oral pill is the next step beyond monthly injections. We covered the Dovato vs Biktarvy head-to-head and Cabenuva’s adolescent superiority data in prior analysis. ISL/LEN leapfrogs both.

4. Atea bemnifosbuvir/ruzasvir (Phase 3 complete): Good data, market does not care

Atea Pharmaceuticals (AVIR) closed at $4.62 with a $370 million market cap. The C-BEYOND Phase 3 trial showed bemnifosbuvir/ruzasvir achieved cure rates matching Epclusa (sofosbuvir/velpatasvir) in hepatitis C. We analyzed the Atea (AVIR) bemnifosbuvir/ruzasvir HCV Phase 3 data in our prior coverage.

The HCV cure market is commoditized. Gilead’s Epclusa and Harvoni transformed HCV from a growth story into a declining annuity. Atea’s data is real, but the market does not care because HCV is a solved clinical problem with entrenched generics. At $370M market cap, Atea is priced for irrelevance. Even if bemnifosbuvir/ruzasvir is approved, the commercial opportunity is marginal in a commoditized market. This is a skip for investors. Good science does not override a bad market structure.

5. Moderna mRNA-1345 RSV: The vaccine platform question

Moderna (MRNA) closed at $54.49 with a $21.6 billion market cap. The RSV vaccine market is a three-player race: GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia (mRNA-1345, approved in 2024). Post-pandemic, the vaccine market has normalized and RSV vaccine uptake has been below initial expectations.

Moderna’s thesis is platform validation: if mRNA works for RSV, it works for more than COVID. We analyzed the Moderna/BioNTech platform thesis in our prior coverage. At $21.6B, MRNA is pricing in platform optionality, but the RSV franchise alone does not justify the valuation. The next real catalyst for Moderna is the flu vaccine PDUFA, not RSV. RSV is a proof-of-concept revenue stream, not a thesis.

Verdict: ranked by risk-reward

1. GSK/Ionis bepirovirsen (Oct 26 PDUFA): The only first-in-class functional cure on this list. 19% cure rate vs 0% placebo in a 250-million-patient disease. GSK at $106.6B will not move much on approval, but IONS at $8.93B gets platform validation and royalties. Buy IONS ahead of the PDUFA.

2. GILD/MRK ISL/LEN weekly (early 2027 PDUFA): The real HIV dosing shift. A weekly pill is the next step beyond daily Biktarvy and monthly Cabenuva. Both GILD and MRK are mega-caps where this is immaterial to the stock, but the clinical impact is the largest on this list.

3. GILD BIC/LEN (Aug 27 PDUFA): Approval is likely, but the net revenue is near-zero because Gilead is cannibalizing its own Biktarvy. Hold GILD, do not buy for this catalyst.

4. Moderna mRNA-1345 RSV: Platform proof-of-concept, not a stock-mover. The real catalyst is the flu vaccine PDUFA, not RSV.

5. Atea bemnifosbuvir/ruzasvir: Skip. HCV is commoditized and Atea at $370M is priced for irrelevance. Good data does not overcome bad market structure.

The contrarian takeaway: the most exciting infectious disease catalyst of 2026 is not in HIV. It is in hepatitis B, a disease most investors have stopped watching. Bepirovirsen at 19% functional cure against a 0% baseline is the data package that matters. Everything else is mega-cap maintenance or commoditized-market noise.